Skip to main content
. 2017 Jan-Feb;21(1):210–230. doi: 10.4103/2230-8210.196029

Table 3.

Counseling for risks associated with sodium-glucose co-transporter 2 inhibitor therapy

graphic file with name IJEM-21-210-g012.jpg